AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Verastem Soars 16.58% on Positive NSCLC Trial Data
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Aug 14, 2025 5:11 am ET1min read
Aime SummaryOn August 14, 2025, Verastem's stock surged by 16.58% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
Verastem Oncology recently announced a late-breaking abstract from a study conducted by its partner, GenFleet Therapeutics, which demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) patients at the recommended Phase 2 dose of 600 mg QD. This data is part of a phase 1/2 trial in China, focusing on NSCLC patients with a KRAS mutation.
Additionally,
reported that the U.S. IND for VS-7375 has been cleared, and a Phase 1/2a trial has been initiated. This development is crucial as it paves the way for further clinical trials and potential approvals, which could significantly impact the company's future prospects.The positive results from the GFH375 trial have been well-received by the market, contributing to the recent surge in Verastem's stock price. The company's focus on oncology and its innovative approach to treating NSCLC have positioned it as a key player in the biotech industry.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
United States Antimony (UAMY) Surges 5.31% on Year-End Portfolio Adjustments by Institutional Investors
Dec.26 2025
Strive Asset Management (NASDAQ:ASST) surges 7.03% on strategic dividend adjustment to 12.25% from 12%
Dec.26 2025
Sweetgreen (NYSE:SG) surges 5.41% on strategic expansion and new Sacramento locations
Dec.26 2025
Autozi Internet shares surge 13.54% on strategic initiatives and autonomous vehicle developments
Dec.26 2025
Strive surges 7.03% as delisting concerns and dividend boost drive buying
Dec.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet